Has Nitin Jain, MD received payments from drug or device companies?

Yes. Drug and device makers reported $33,238,416 in general payments to Nitin Jain, MD across 402 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nitin Jain, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nitin Jain, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nitin Jain, MD

Internal Medicine · Houston, TXNPI 1659459113

Payments from drug & device makers

$33,238,416in general payments, 2019–2025

Across 402 payments — averaging $82,683 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$25.5M
Pharmacyclics LLC, An Abbvie Company$1.6M
Eli Lilly$1.5M
Takeda Pharmaceuticals U.S.A., Inc.$1.1M
Genentech, Inc.$1M
Astrazeneca UK Limited$869K
plus $1.6M from 30 others

$1,498in research payments, 2019–2025

Across 5 payments — averaging $299.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$745
AbbVie$713
Pharmacyclics LLC, An Abbvie Company$41

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	108	$25,519,918
Pharmacyclics LLC, An Abbvie Company	15	$1,625,876
Eli Lilly	6	$1,500,549
Takeda Pharmaceuticals U.S.A., Inc.	4	$1,112,502
Genentech, Inc.	17	$1,048,426
Astrazeneca UK Limited	27	$869,230
Gilead(2 entities)	36	$482,458
Pfizer	7	$318,102
Institut DE Recherches Internationales Servier	16	$184,531
Beone Medicines USA, Inc.	8	$132,902
Beone Medicines Ltd.	10	$115,336
Jazz Pharmaceuticals Inc.	2	$95,437
Verastem, Inc.	1	$41,925
AstraZeneca	26	$40,259
Adaptive Biotechnologies Corporation	7	$35,573
Lilly USA, LLC	14	$32,959
Hikma Pharmaceuticals USA	12	$30,686
Beigene USA, Inc.	11	$16,459
Genentech USA, Inc.	8	$7,844
Janssen Scientific Affairs, LLC	3	$7,715
Janssen Research & Development, LLC	4	$6,518
E.r. Squibb & Sons, L.L.C.	2	$4,151
Ipsen Biopharmaceuticals, Inc	1	$3,915
Beigene, Ltd.	1	$1,300
BTG International Inc.	2	$1,068
Servier Bioinnovation	1	$846
Johnson & Johnson	33	$551
Bristol Myers Squibb	5	$313
ADC Therapeutics America, Inc.	2	$297
Janssen Global Services, LLC	1	$273
Rigel Pharmaceuticals, Inc.	2	$220
Astellas Pharma US Inc	2	$96
Boehringer Ingelheim	5	$85
Incyte Corporation	1	$58
Medtronic	1	$24
Actelion Pharmaceuticals US, Inc.	1	$14

How this compares

$33,238,416 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024

$88,633

Medicare patients

254

Services billed

802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Houston

Jan BurgerHouston$47.3M
Aung NaingHouston$30.6M
Preetesh JainHouston$19.5M
Paolo StratiHouston$19.2M
Nicholas ShortHouston$17.6M
Isabella GlitzaHouston$14.8M
Murtaza MussajiHouston$13.1M
Hussein TawbiHouston$12.6M
Hans LeeHouston$11.7M
Dominick DaunnoHouston$11.1M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →